vs
Side-by-side financial comparison of Blue Bird Corp (BLBD) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($346.4M vs $333.1M, roughly 1.0× Blue Bird Corp). HAEMONETICS CORP runs the higher net margin — 28.1% vs 9.2%, a 18.9% gap on every dollar of revenue. On growth, Blue Bird Corp posted the faster year-over-year revenue change (6.1% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $31.1M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -1.9%).
The Blue Bird Corporation is an American bus manufacturer. Headquartered in Fort Valley, Georgia, the company was best known for its production of school buses. The company has also manufactured a wide variety of other bus types, including transit buses, motorhomes, and specialty vehicles such as mobile libraries and mobile police command centers.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
BLBD vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $333.1M | $346.4M |
| Net Profit | $30.8M | $97.3M |
| Gross Margin | 21.4% | 57.2% |
| Operating Margin | 11.3% | 36.1% |
| Net Margin | 9.2% | 28.1% |
| Revenue YoY | 6.1% | 4.8% |
| Net Profit YoY | 7.1% | — |
| EPS (diluted) | $0.94 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $333.1M | $339.0M | ||
| Q3 25 | $409.4M | $327.3M | ||
| Q2 25 | $398.0M | $321.4M | ||
| Q1 25 | $358.9M | $330.6M | ||
| Q4 24 | $313.9M | $348.5M | ||
| Q3 24 | $350.2M | $345.5M | ||
| Q2 24 | $333.4M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $30.8M | $44.7M | ||
| Q3 25 | $36.5M | $38.7M | ||
| Q2 25 | $36.5M | $34.0M | ||
| Q1 25 | $26.0M | $58.0M | ||
| Q4 24 | $28.7M | $37.5M | ||
| Q3 24 | $24.7M | $33.8M | ||
| Q2 24 | $28.7M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | 21.4% | 59.7% | ||
| Q3 25 | 21.1% | 59.5% | ||
| Q2 25 | 21.6% | 59.8% | ||
| Q1 25 | 19.7% | 58.4% | ||
| Q4 24 | 19.2% | 55.5% | ||
| Q3 24 | 17.0% | 54.2% | ||
| Q2 24 | 20.8% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 11.3% | 19.9% | ||
| Q3 25 | 12.3% | 17.9% | ||
| Q2 25 | 12.6% | 16.8% | ||
| Q1 25 | 9.4% | 21.6% | ||
| Q4 24 | 10.5% | 16.9% | ||
| Q3 24 | 7.3% | 15.0% | ||
| Q2 24 | 11.9% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 9.2% | 13.2% | ||
| Q3 25 | 8.9% | 11.8% | ||
| Q2 25 | 9.2% | 10.6% | ||
| Q1 25 | 7.3% | 17.5% | ||
| Q4 24 | 9.2% | 10.8% | ||
| Q3 24 | 7.0% | 9.8% | ||
| Q2 24 | 8.6% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.94 | $0.95 | ||
| Q3 25 | $1.11 | $0.81 | ||
| Q2 25 | $1.12 | $0.70 | ||
| Q1 25 | $0.79 | $1.17 | ||
| Q4 24 | $0.86 | $0.74 | ||
| Q3 24 | $0.71 | $0.66 | ||
| Q2 24 | $0.85 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $241.7M | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $271.4M | $796.3M |
| Total Assets | $642.3M | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $241.7M | $363.4M | ||
| Q3 25 | $229.3M | $296.4M | ||
| Q2 25 | $173.1M | $292.9M | ||
| Q1 25 | $130.7M | $306.8M | ||
| Q4 24 | $136.1M | $320.8M | ||
| Q3 24 | $127.7M | $299.3M | ||
| Q2 24 | $88.4M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $271.4M | $911.5M | ||
| Q3 25 | $255.4M | $849.2M | ||
| Q2 25 | $221.8M | $882.3M | ||
| Q1 25 | $190.4M | $820.8M | ||
| Q4 24 | $179.7M | $906.9M | ||
| Q3 24 | $159.6M | $878.9M | ||
| Q2 24 | $137.3M | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $642.3M | $2.5B | ||
| Q3 25 | $625.3M | $2.4B | ||
| Q2 25 | $575.5M | $2.5B | ||
| Q1 25 | $543.7M | $2.5B | ||
| Q4 24 | $535.2M | $2.5B | ||
| Q3 24 | $524.9M | $2.5B | ||
| Q2 24 | $468.1M | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $36.6M | $293.2M |
| Free Cash FlowOCF − Capex | $31.1M | $209.9M |
| FCF MarginFCF / Revenue | 9.3% | 60.6% |
| Capex IntensityCapex / Revenue | 1.6% | 9.5% |
| Cash ConversionOCF / Net Profit | 1.19× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $162.6M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $36.6M | $93.6M | ||
| Q3 25 | $65.1M | $111.3M | ||
| Q2 25 | $56.9M | $17.4M | ||
| Q1 25 | $27.8M | $116.6M | ||
| Q4 24 | $26.4M | $43.8M | ||
| Q3 24 | $55.4M | $48.8M | ||
| Q2 24 | $989.0K | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $31.1M | $87.2M | ||
| Q3 25 | $60.5M | $106.3M | ||
| Q2 25 | $52.3M | $13.6M | ||
| Q1 25 | $18.7M | $100.9M | ||
| Q4 24 | $21.8M | $35.2M | ||
| Q3 24 | $50.2M | $39.4M | ||
| Q2 24 | $-3.5M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 9.3% | 25.7% | ||
| Q3 25 | 14.8% | 32.5% | ||
| Q2 25 | 13.1% | 4.2% | ||
| Q1 25 | 5.2% | 30.5% | ||
| Q4 24 | 7.0% | 10.1% | ||
| Q3 24 | 14.3% | 11.4% | ||
| Q2 24 | -1.1% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 1.6% | 1.9% | ||
| Q3 25 | 1.1% | 1.5% | ||
| Q2 25 | 1.2% | 1.2% | ||
| Q1 25 | 2.5% | 4.7% | ||
| Q4 24 | 1.5% | 2.5% | ||
| Q3 24 | 1.5% | 2.7% | ||
| Q2 24 | 1.3% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 1.19× | 2.09× | ||
| Q3 25 | 1.78× | 2.88× | ||
| Q2 25 | 1.56× | 0.51× | ||
| Q1 25 | 1.07× | 2.01× | ||
| Q4 24 | 0.92× | 1.17× | ||
| Q3 24 | 2.24× | 1.44× | ||
| Q2 24 | 0.03× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLBD
| Alternative Fuel Buses | $151.4M | 45% |
| Diesel Buses | $144.9M | 43% |
| Parts | $24.8M | 7% |
| Other | $12.1M | 4% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
